Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05802680 · ClinicalTrials.gov registry record · NA

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

A NA study of Attention Deficit Hyperactivity Disorder and Wellness, sponsored by University of Texas at Austin.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
1
Study location

NCT05802680: Recruiting NA study of Attention Deficit Hyperactivity Disorder and Wellness, sponsored by University of Texas at Austin.

NCT05802680 is a NA study of Attention Deficit Hyperactivity Disorder and Wellness that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 500 participants, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (136% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05802680, a NA study of Attention Deficit Hyperactivity Disorder and Wellness, is actively recruiting participants, sponsored by University of Texas at Austin.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe and non-invasive modality for activation of the prefrontal cortex. tPBM in healthy adults has been shown to augment brain oxygenation, cognition, and mood. The cognition-enhancing effect of tPBM on sustained attention in adults with ADHD remains unstudied. The investigators will evaluate whether tPBM administration to adults with and without ADHD can improve their attention. Each participant will be screened for eighteen criteria based on the Diagnostic and Statistical Manual (DSM-IV, text revised), using the validated instrument Adult ADHD Self-Report Scale (ASRS-v1.1). Blinded participants will be randomized into (I) Active-tPBM or (II) Sham-tPBM groups. After undergoing an 8-minute administration of Sham or 1064 nm tPBM to the lateral and medial right prefrontal cortex, each participant will complete a 14-minute, computer-based Conner's continuous performance task-3 (CPT-3). The investigators will examine whether adults with and without ADHD who receive Active-tPBM improve in measures of inattention, impulsivity, sustained attention, or vigilance compared to the Sham-tPBM group. Cognitive assessments of attention like the CPT-3 may evaluate the efficacy of tPBM to increase cortical metabolism in healthy adults and individuals with conditions like ADHD. The investigators anticipate their investigation will be a starting point for more sophisticated studies that focus on the implications of tPBM on cognition.

Primary Outcome

Measure of inattention, impulsivity, sustained attention, vigilance

Conditions Studied

Attention Deficit Hyperactivity Disorder Wellness Attention Difficulties Cognitive Deficit Attention-deficit

Interventions

  • DEVICE Transcranial photobiomodulation
  • DEVICE Sham transcranial photobiomodulation

Study Locations (1)

Texas

  • The University of Texas at Austin - Austin

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-02-09
Est. Completion 2027-02-01
Phase NA
University of Texas at Austin

257 total trials

What NCT05802680 shows while recruiting

NCT05802680 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (136% higher).

The record links to 5 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Transcranial photobiomodulation is the first listed.

NCT05802680 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05802680 about?

NCT05802680 is a clinical study titled "Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation". Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe...

What is the current status of trial NCT05802680?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-02-09. Estimated completion is 2027-02-01.

What conditions does trial NCT05802680 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Wellness, Attention Difficulties, Cognitive Deficit, Attention-deficit.

What interventions are being tested in trial NCT05802680?

The interventions under investigation include: Transcranial photobiomodulation (DEVICE), Sham transcranial photobiomodulation (DEVICE).

Who is sponsoring clinical trial NCT05802680?

This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05802680 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05802680's enrollment target sits among peer trials

500 9th of 102 higher than 93 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05802680

Source: ClinicalTrials.gov NCT05802680, the US trial registry maintained by the National Library of Medicine. NCT05802680 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.